132 related articles for article (PubMed ID: 37952507)
21. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
[TBL] [Abstract][Full Text] [Related]
22. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.
Kawaguchi H; El-Naggar AK; Papadimitrakopoulou V; Ren H; Fan YH; Feng L; Lee JJ; Kim E; Hong WK; Lippman SM; Mao L
J Clin Oncol; 2008 Jan; 26(3):354-60. PubMed ID: 18202409
[TBL] [Abstract][Full Text] [Related]
23. Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms.
Ochoa-Alvarez JA; Krishnan H; Pastorino JG; Nevel E; Kephart D; Lee JJ; Retzbach EP; Shen Y; Fatahzadeh M; Baredes S; Kalyoussef E; Honma M; Adelson ME; Kaneko MK; Kato Y; Young MA; Deluca-Rapone L; Shienbaum AJ; Yin K; Jensen LD; Goldberg GS
Oncotarget; 2015 Apr; 6(11):9045-60. PubMed ID: 25826087
[TBL] [Abstract][Full Text] [Related]
24. Podoplanin expression in tumor-free resection margins of oral squamous cell carcinomas: an immunohistochemical and fractal analysis study.
Margaritescu C; Raica M; Pirici D; Simionescu C; Mogoanta L; Stinga AC; Stinga AS; Ribatti D
Histol Histopathol; 2010 Jun; 25(6):701-11. PubMed ID: 20376776
[TBL] [Abstract][Full Text] [Related]
25. Dual role of podoplanin in oral cancer development.
Cîrligeriu L; Cimpean AM; Raica M; Doroş CI
In Vivo; 2014; 28(3):341-7. PubMed ID: 24815836
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Podoplanin in Oral Leukoplakia and Oral Squamous Cell Carcinoma.
Patil A; Patil K; Tupsakhare S; Gabhane M; Sonune S; Kandalgaonkar S
Scientifica (Cairo); 2015; 2015():135298. PubMed ID: 26558136
[TBL] [Abstract][Full Text] [Related]
27. Podoplanin expression correlates with sentinel lymph node metastasis in early squamous cell carcinomas of the oral cavity and oropharynx.
Huber GF; Fritzsche FR; Züllig L; Storz M; Graf N; Haerle SK; Jochum W; Stoeckli SJ; Moch H
Int J Cancer; 2011 Sep; 129(6):1404-9. PubMed ID: 21105028
[TBL] [Abstract][Full Text] [Related]
28. Interaction between oral squamous cell carcinoma cells and fibroblasts through TGF-β1 mediated by podoplanin.
Li YY; Zhou CX; Gao Y
Exp Cell Res; 2018 Aug; 369(1):43-53. PubMed ID: 29719198
[TBL] [Abstract][Full Text] [Related]
29. Podoplanin and VEGF-C immunoexpression in oral squamous cell carcinomas: prognostic significance.
dos Santos Almeida A; Oliveira DT; Pereira MC; Faustino SE; Nonogaki S; Carvalho AL; Kowalski LP
Anticancer Res; 2013 Sep; 33(9):3969-76. PubMed ID: 24023336
[TBL] [Abstract][Full Text] [Related]
30. Bioactive phytocompounds for oral cancer prevention and treatment: A comprehensive and critical evaluation.
Burcher JT; DeLiberto LK; Allen AM; Kilpatrick KL; Bishayee A
Med Res Rev; 2023 Nov; 43(6):2025-2085. PubMed ID: 37143373
[TBL] [Abstract][Full Text] [Related]
31. Expression of podoplanin in the invasion front of oral squamous cell carcinoma is not prognostic for survival.
de Vicente JC; Santamarta TR; Rodrigo JP; García-Pedrero JM; Allonca E; Blanco-Lorenzo V
Virchows Arch; 2015 May; 466(5):549-58. PubMed ID: 25726183
[TBL] [Abstract][Full Text] [Related]
32. Expression of podoplanin and ABCG2 in oral erythroplakia correlate with oral cancer development.
Feng JQ; Mi JG; Wu L; Ma LW; Shi LJ; Yang X; Liu W; Zhang CP; Zhou ZT
Oral Oncol; 2012 Sep; 48(9):848-52. PubMed ID: 22525603
[TBL] [Abstract][Full Text] [Related]
33. An immunohistochemical evaluation of podoplanin expression in oral leukoplakia and oral squamous cell carcinoma to explore its potential to be used as a predictor for malignant transformation.
Aiswarya A; Suresh R; Janardhanan M; Savithri V; Aravind T; Mathew L
J Oral Maxillofac Pathol; 2019; 23(1):159. PubMed ID: 31110440
[TBL] [Abstract][Full Text] [Related]
34. Podoplanin expression predicts prognosis in patients with oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy.
Kreppel M; Drebber U; Wedemeyer I; Eich HT; Backhaus T; Zöller JE; Scheer M
Oral Oncol; 2011 Sep; 47(9):873-8. PubMed ID: 21767977
[TBL] [Abstract][Full Text] [Related]
35. Carcinogenesis of the Oral Cavity: Environmental Causes and Potential Prevention by Black Raspberry.
El-Bayoumy K; Chen KM; Zhang SM; Sun YW; Amin S; Stoner G; Guttenplan JB
Chem Res Toxicol; 2017 Jan; 30(1):126-144. PubMed ID: 28092946
[TBL] [Abstract][Full Text] [Related]
36. Platelet-activating factor podoplanin: from discovery to drug development.
Takemoto A; Miyata K; Fujita N
Cancer Metastasis Rev; 2017 Jun; 36(2):225-234. PubMed ID: 28674748
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of SOX2 and podoplanin expression in oral epithelial dysplasia and its correlation with malignant transformation.
Verma V; Chandrashekar C
J Investig Clin Dent; 2019 Nov; 10(4):e12450. PubMed ID: 31464104
[TBL] [Abstract][Full Text] [Related]
38. PD-1 blockade prevents the progression of oral carcinogenesis.
Dong Y; Wang Z; Mao F; Cai L; Dan H; Jiang L; Zeng X; Li T; Zhou Y; Chen Q
Carcinogenesis; 2021 Jun; 42(6):891-902. PubMed ID: 33993220
[TBL] [Abstract][Full Text] [Related]
39. Local Anti-PD-1 Delivery Prevents Progression of Premalignant Lesions in a 4NQO-Oral Carcinogenesis Mouse Model.
Shi Y; Xie TX; Leach DG; Wang B; Young S; Osman AA; Sikora AG; Ren X; Hartgerink JD; Myers JN; Rangel R
Cancer Prev Res (Phila); 2021 Aug; 14(8):767-778. PubMed ID: 34021022
[TBL] [Abstract][Full Text] [Related]
40. The immunohistochemical characterization of MMP-2, MMP-10, TIMP-1, TIMP-2, and podoplanin in oral squamous cell carcinoma.
Mashhadiabbas F; Mahjour F; Mahjour SB; Fereidooni F; Hosseini FS
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Aug; 114(2):240-50. PubMed ID: 22769410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
